Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 83
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Apoptosis ; 28(7-8): 1184-1197, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37179285

RESUMEN

This study was designed to assess the ameliorative effects of eugenol and to propose the possible mechanisms of action of eugenol in diethylnitrosamine (DENA)/acetylaminofluorene (AAF)-caused lung cancer in Wistar rats. To induce lung cancer, DENA at a dose of 150 mg/kg body weight (b.wt) for 2 weeks were intraperitoneally injected once each week and AAF was administered orally at a dose of 20 mg/kg b.wt. four times each week for the next 3 weeks. DENA/AAF-administered rats were orally supplemented with eugenol at a dose of 20 mg/kg b.wt administered once a day until 17 weeks starting from the 1st week of DENA administration. Lung histological lesions, including sheets of tumor cells, micropapillary adenocarcinoma, and apoptotic cells, resulting from the DENA/AAF dosage, were ameliorated by eugenol treatment. However, a significant drop in the levels of LPO in the lungs and a remarkable rise in GSH content and GPx and SOD activities were observed in DENA/AAF-administered rats treated with eugenol compared with those in DENA/AAF-administered controls. Moreover, in DENA/AAF-administered rats, eugenol supplementation significantly reduced TNF-α and IL-1ß levels and mRNA expression levels of NF-κB, NF-κB p65, and MCP-1 but significantly elevated the level of Nrf2. Furthermore, the DENA/AAF-administered rats treated with eugenol exhibited a significant downregulation of Bcl-2 expression levels in addition to a significant upregulation in P53 and Bax expression levels. Otherwise, the administration of DENA/AAF elevated the protein expression level of Ki-67, and this elevation was reversed by eugenol treatment. In conclusion, eugenol has effective antioxidant, anti-inflammatory, proapoptotic, and antiproliferative properties against lung cancer.


Asunto(s)
Anticarcinógenos , Neoplasias Hepáticas Experimentales , Neoplasias Pulmonares , Ratas , Animales , Ratas Wistar , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , 2-Acetilaminofluoreno/efectos adversos , 2-Acetilaminofluoreno/metabolismo , Dietilnitrosamina/toxicidad , Dietilnitrosamina/metabolismo , Eugenol/efectos adversos , FN-kappa B/genética , FN-kappa B/metabolismo , Apoptosis , Neoplasias Pulmonares/inducido químicamente , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/metabolismo , Hígado/patología , Neoplasias Hepáticas Experimentales/inducido químicamente , Neoplasias Hepáticas Experimentales/metabolismo , Neoplasias Hepáticas Experimentales/patología
2.
Reprod Fertil Dev ; 30(3): 487-497, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28814372

RESUMEN

Cytochrome P450 aromatase (encoded by the CYP19A1 gene) regulates oestrogen biosynthesis and so plays an essential role in female fertility. We investigated the genetic association of CYP19A1 with the risk of anoestrus in Egyptian water buffaloes. A total of 651 animals (326 anoestrous and 325 cycling) were used in this case-control study. Using single-strand conformation polymorphisms and sequencing, four single nucleotide polymorphisms (SNPs) were detected; c.-135T>C SNP in the 5'UTR and three non-synonymous SNPs: c.559G>A (p. V187M) in Exon 5, c.1285C>T (p. P429S) and c.1394A>G (p. D465G) in Exon 10. Individual SNP-anoestrus association analyses revealed that genotypes (CC, AA and GG) and alleles (C, A and G) of the -135T>C, c.559G>A and c.1394A>G SNPs respectively were high risk for anoestrus. A further analysis confirmed that these three SNPs were in linkage disequilibrium. Additionally, haplotypes with two (TAG/122 and CAA/221) or three (CAG/222) risk alleles were significantly associated with susceptibility to anoestrus, lower blood levels of both oestradiol and antioxidant enzymes (superoxide dismutase, glutathione peroxidase (GPX) and catalase) and downregulated expression levels of CYP19A1, oestrogen receptor α and Gpx3 in the ovary, as well as increased serum level of malondialdehyde. This suggests the occurrence of a high incidence of oxidative ovarian damage and subsequently ovarian inactivity in buffaloes carrying risk alleles. Therefore, with this study we suggest the selection of buffaloes with protective alleles at these SNPs to improve the reproductive efficiency of the herd.


Asunto(s)
Anestro/genética , Aromatasa/genética , Búfalos/genética , Ovario/enzimología , Polimorfismo de Nucleótido Simple , Regiones no Traducidas 5' , Anestro/sangre , Animales , Biomarcadores/sangre , Búfalos/sangre , Catalasa/sangre , Estradiol/sangre , Receptor alfa de Estrógeno/metabolismo , Exones , Femenino , Frecuencia de los Genes , Glutatión Peroxidasa/sangre , Haplotipos , Heterocigoto , Homocigoto , Desequilibrio de Ligamiento , Malondialdehído/sangre , Estrés Oxidativo , Fenotipo , Superóxido Dismutasa/sangre
3.
J Viral Hepat ; 24(4): 262-267, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28145032

RESUMEN

Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the highest prevalence rate worldwide. This necessitated establishing a novel model of care (MOC) to contain the epidemic, deliver patient care and ensure global treatment access. In this review, we describe the process of development of the Egyptian model and future strategies for sustainability. Although the magnitude of the HCV problem was known for many years, the HCV MOC only came into being in 2006 with the establishment of the National Committee for Control of Viral Hepatitis (NCCVH) to set up and implement a national control strategy for the disease and other causes of viral hepatitis. The strategy outlines best practices for patient care delivery by applying a set of service principles through identified clinical streams and patient flow continuums. The Egyptian national viral hepatitis treatment programme is considered one of the most successful and effective public health programmes. To date, more than one million patients were evaluated and more than 850 000 received treatment under the umbrella of the programme since 2006. The NCCVH has been successful in establishing a strong infrastructure for controlling viral hepatitis in Egypt. It established a nationwide network of digitally connected viral hepatitis-specialized treatment centres covering the country map to enhance treatment access. Practice guidelines suiting local circumstances were issued and regularly updated and are applied in all affiliated centres. This review illustrates the model and the successful Egyptian experience. It sets an exemplar for states, organizations and policy-makers setting up programmes for care and management of people with hepatitis C.


Asunto(s)
Atención a la Salud/organización & administración , Manejo de la Enfermedad , Hepatitis C Crónica/diagnóstico , Hepatitis C Crónica/tratamiento farmacológico , Administración en Salud Pública/métodos , Antivirales/uso terapéutico , Egipto/epidemiología , Hepatitis C Crónica/epidemiología , Humanos , Guías de Práctica Clínica como Asunto
4.
Brain Behav Immun ; 61: 146-154, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28034626

RESUMEN

Autism spectrum disorders (ASD) affect millions of children worldwide, and are characterized by impairment in social interaction and communication, and specific repetitive behavioral patterns. Growing evidence highlights a role of toll-like receptors (TLRs) in the pathogenesis of ASD. Specifically, TLR-4 activation has been shown to be associated with increased pro-inflammatory cytokines as well as autistic symptoms in offspring. NADPH oxidase (NOX-2) derived reactive oxygen species (ROS) have also been shown to play pathogenic role under inflammatory conditions. However, the role of TLR-4 in the regulation of NOX-2 derived ROS has not been explored in ASD, particularly in T cells. Therefore, this study explored TLR-4 and NOX-2 related signaling in peripheral T cells of ASD patients (n=35) and age-matched typically developing children (n=30). In this study, we find that ASD individuals have increased TLR-4 expression on T cells which is associated with increased NOX-2 expression and ROS generation as compared to typically developing children. Moreover, activation of TLR-4 on T cells by lipopolysaccharide (LPS) in vitro leads to enhanced generation of NOX-2 derived ROS via nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. These data support a link between T cell TLR-4 activation and NOX-2/ROS upregulation in ASD patients. Our study has implications in the context of neuroinflammation observed in ASD patients as ROS may lead to amplification and perpetuation of inflammation both in the periphery and central nervous system. Our data also suggest that therapeutic targeting of TLR-4 signaling may lead to reduction in inflammation of ASD patients.


Asunto(s)
Trastorno Autístico/metabolismo , NADPH Oxidasas/metabolismo , Transducción de Señal/fisiología , Linfocitos T/metabolismo , Receptor Toll-Like 4/metabolismo , Regulación hacia Arriba/fisiología , Trastorno Autístico/genética , Niño , Preescolar , Femenino , Humanos , Masculino , NADPH Oxidasas/genética , FN-kappa B/metabolismo , Especies Reactivas de Oxígeno/metabolismo
5.
Mol Cell Neurosci ; 77: 1-10, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27693537

RESUMEN

Autism is a neurodevelopmental disorder categorized by qualitative impairments in social interaction, communication, and repetitive stereotypic behavior. Emerging evidence increasingly suggests that chemokine receptors have a pivotal role in the central nervous system and are involved in the pathogenesis of numerous neuroinflammatory diseases. Resveratrol is widely used to treat neurodegenerative diseases, but its effect on autism has not been investigated. We investigated the effect of resveratrol (20 and 40mg/kg) in the spleen and brain tissues of BTBR T+tf/J (BTBR) and C57BL/6J (B6) mice as well as on the C-C chemokine receptor (CCR) and C-X-C motif chemokine receptor (CXCR) (CCR3+, CCR5+, CCR7+ and CCR9+, CXCR3+ and CXCR5+) in cluster of differentiation 4-positive (CD4+) T cells in the spleen. We also assessed the mRNA expression of CCR and CXCR receptors in the spleen and brain tissues. Our study revealed that the BTBR and B6 control mice showed different immune profiles. The BTBR mice showed characteristic higher levels of both CCR and CXCR production and expression in CD4+ T cells than the B6 control mice did. Treatment of B6 and BTBR mice with resveratrol (20 and 40mg/kg) induced a substantial decrease in the CCR and CXCR production and expression in CD4+ T cells compared with the respective untreated control groups. Moreover, resveratrol treatment decreased the mRNA expression levels of CCR and CXCR in the spleen and brain tissues. Resveratrol downregulated the chemokine receptor levels, which might provide unique targets for future therapies for autism.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Trastorno Autístico/metabolismo , Receptores de Quimiocina/metabolismo , Estilbenos/farmacología , Animales , Encéfalo/citología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Células Cultivadas , Masculino , Ratones , Ratones Endogámicos C57BL , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores de Quimiocina/genética , Resveratrol , Bazo/citología , Bazo/efectos de los fármacos , Bazo/metabolismo
6.
Saudi Pharm J ; 25(1): 120-127, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28223872

RESUMEN

This study aimed to evaluate the protective effect of chitosan (CS) against hypercholesterolemia (HC) induced arginase activation and disruption of nitric oxide (NO) biosynthesis using erythrocytes as cellular model. Human erythrocytes were isolated and classified into eight groups. Next, cells were treated with l-arginine (l-ARG), Nω-nitro-l-arginine methyl ester (l-NAME), CS or CS + l-ARG in the presence of normal plasma or cholesterol enriches plasma. Then, erythrocytes were incubated at 37 °C for 24 h. The present results revealed that, HC induced significant increase of cholesterol inclusion into erythrocytes membrane compared to control. Moreover, HC caused significant decrease in nitric oxide synthase (NOS) activity similar to l-NAME; however, arginase activity and arginase/NOS ratio significantly increased compared to control. On contrast, treatment of HC with, l-arginine, CS or CS plus l-arginine prevents HC induced cholesterol loading into erythrocytes membrane, NOS inhibition and arginase activation. This study suggested that CS could be protective agent against HC induced disruption of erythrocyte's oxidative status and arginase activation.

7.
Mol Cell Biochem ; 416(1-2): 141-55, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27084536

RESUMEN

Medulloblastoma (MB) is the most common malignant brain tumor of childhood. The transcription factor NF-κB is overexpressed in human MB and is a critical factor for MB tumor growth. NF-κB is known to regulate the expression of interleukin-8 (IL-8), the chemokine that enhances cancer cell growth and resistance to chemotherapy. We have recently shown that thymoquinone (TQ) suppresses growth of hepatocellular carcinoma cells in part by inhibiting NF-κB signaling. Here we sought to extend these studies in MB cells and show that TQ suppresses growth of MB cells in a dose- and time-dependent manner, causes G2M cell cycle arrest, and induces apoptosis. TQ significantly increased generation of reactive oxygen species (ROS), while pretreatment of MB cells with the ROS scavenger N-acetylcysteine (NAC) abrogated TQ-induced cell death and apoptosis, suggesting that TQ-induced cell death and apoptosis are oxidative stress-mediated. TQ inhibitory effects were associated with inhibition of NF-κB and altered expression of its downstream effectors IL-8 and its receptors, the anti-apoptotic Bcl-2, Bcl-xL, X-IAP, and FLIP, as well as the pro-apoptotic TRAIL-R1, caspase-8, caspase-9, Bcl-xS, and cytochrome c. TQ-triggered apoptosis was substantiated by up-regulation of the executioner caspase-3 and caspase-7, as well as cleavage of the death substrate poly(ADP-ribose)polymerase. Interestingly, pretreatment of MB cells with NAC or the pan-caspase inhibitor zVAD-fmk abrogated TQ-induced apoptosis, loss of cyclin B1 and NF-κB activity, suggesting that these TQ-mediated effects are oxidative stress- and caspase-dependent. These findings reveal that TQ induces both extrinsic and intrinsic pathways of apoptosis in MB cells, and suggest its potential usefulness in the treatment of MB.


Asunto(s)
Apoptosis/efectos de los fármacos , Benzoquinonas/farmacología , Caspasas/metabolismo , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Interleucina-8/biosíntesis , Meduloblastoma/metabolismo , FN-kappa B/metabolismo , Proteínas de Neoplasias/metabolismo , Estrés Oxidativo/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Caspasas/genética , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica/genética , Humanos , Interleucina-8/genética , Meduloblastoma/genética , Meduloblastoma/patología , FN-kappa B/genética , Proteínas de Neoplasias/genética , Transducción de Señal/genética
8.
Immunol Invest ; 45(4): 349-69, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27104958

RESUMEN

Dexamethasone (DEX) is a synthetic glucocorticoid with potent anti-inflammatory effects that is widely used to treat inflammatory diseases. The aim of the present study was to investigate the possible protective effect of DEX on the lipopolysaccharides (LPS)-induced acute lung injury (ALI) in a mouse model. Animals were pretreated with DEX (5 and 10 mg/kg, i.p.) for seven days and acute lung injury was induced by intranasal (i.n.) administration of LPS on day 7. In the present study, administration of LPS resulted in significant increase in neutrophils and lymphocytes count whereas a substantial reduction in T cell subsets (CD3(+) and CD4(+)) and pro-inflammatory (IL-6 and TNF-α) cytokines occurred, which were reversed by DEX treatment. RT-PCR analysis revealed an increased mRNA expression of IL-6, TNF-α, COX-2, iNOS, and NF-κB p65 and decreased IL-10 in the LPS group, which were reversed by treatment with DEX in lung tissues. Western blot analysis revealed an increased expression of COX-2, iNOS and NF-κB p65 in the LPS-group, which was reduced by treatment with DEX. Compared with the LPS group, the DEX treatment also demonstrated a considerable increase in the protein expression level of IL-10 cytokine. Administration of LPS resulted in marked increase in malondialdehyde (MDA) levels and myeloperoxidase (MPO) activity whereas noticeable decrease in glutathione (GSH) content. These changes were significantly reversed by treatment with DEX. The histological examinations revealed protective effect of DEX while LPS group aggravated lung injury. The present findings demonstrate the potent anti-inflammatory action of the DEX against acute lung injury induced by LPS.


Asunto(s)
Lesión Pulmonar Aguda/tratamiento farmacológico , Dexametasona/uso terapéutico , Interleucina-10/metabolismo , Pulmón/efectos de los fármacos , Neutrófilos/efectos de los fármacos , Animales , Células Cultivadas , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Humanos , Mediadores de Inflamación/metabolismo , Interleucina-10/genética , Interleucina-6/genética , Interleucina-6/metabolismo , Lipopolisacáridos/inmunología , Pulmón/patología , Masculino , Ratones , Ratones Endogámicos BALB C , FN-kappa B/genética , FN-kappa B/metabolismo , Neutrófilos/inmunología , Transducción de Señal/efectos de los fármacos , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
9.
Int Immunol ; 26(6): 325-40, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24402309

RESUMEN

Rheumatoid arthritis (RA) is one of the major autoimmune diseases with a global prevalence. Despite significant research into this disease, no drugs with acceptable safety profiles are yet available for its treatment. We investigated the possible anti-arthritic effects of the 4-methylhistamine (4-MeH) histamine 4 receptor (H4R) agonist and the JNJ77777120 (JNJ) H4R antagonist to explore the role of H4R in a mouse model of collagen antibody-induced arthritis (CAIA). Arthritis was induced via intravenous (tail vein) injection of Balb/c mice with a 5-clone cocktail of mAbs against collagen type II, followed by LPS, and the effects of treatment with 4-MeH or JNJ (30 mg kg(-1), i.p, twice daily) for 7 days (prophylactic or therapeutic regimens) were assessed. The results revealed increased paw edema, arthritic scores, joint histological inflammatory damage and matrix metalloproteinase-3 levels and high levels of Th1 pro-inflammatory cytokine mRNA and serum proteins in CAIA mice or following H4R activation via 4-MeH. Additionally, 4-MeH efficiently increased expression levels of NF-κB p65. JNJ-treated mice showed a substantial reduction in all the previously mentioned effects, with a similar trend being observed under prophylactic and therapeutic treatment regimens. The results of the present work indicate that JNJ exhibits significant anti-inflammatory and anti-arthritic activities, demonstrating the clear involvement of H4R antagonism in the pathogenesis and progression of RA.


Asunto(s)
Artritis Experimental/inmunología , Artritis Reumatoide/inmunología , Indoles/administración & dosificación , Metilhistaminas/administración & dosificación , Piperazinas/administración & dosificación , Receptores Acoplados a Proteínas G , Receptores Histamínicos , Células TH1/inmunología , Animales , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Células Cultivadas , Citocinas/metabolismo , Progresión de la Enfermedad , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Inmunofenotipificación , Indoles/efectos adversos , Inyecciones Intraperitoneales , Activación de Linfocitos/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/genética , Metaloproteinasa 3 de la Matriz/metabolismo , Metilhistaminas/efectos adversos , Ratones , Ratones Endogámicos BALB C , FN-kappa B/genética , FN-kappa B/metabolismo , Piperazinas/efectos adversos , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/antagonistas & inhibidores , Receptores Histamínicos H4
10.
Pharmacol Res ; 102: 1-11, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26361726

RESUMEN

Diosmin, a natural flavonoid glycoside present abundantly in the pericarp of various citrus fruits. Because of its anti-inflammatory and antioxidant properties, it can be used in many diseases. In this study, we investigated the possible protective mechanisms of the diosmin on LPS-induced lung injury through inhibition of T cell receptors, pro-inflammatory cytokines and NF-κB activation. Animals were pretreated with diosmin (50 and 100mg/kg, p.o.) for seven days prior to lipopolysaccharides (LPS) treatment. LPS administration increased neutrophils, monocytes, lymphocytes, total leukocyte count (TLC) and platelets which were decreased by diosmin. We observed that mice exposed to LPS showed increased malondialdehyde level and MPO activity whereas marked decrease in glutathione content. These changes were significantly reversed by treatment with diosmin in a dose dependent manner. Diosmin treatment showed a substantial reduction in T cell (CD4(+) and CD8(+)) receptors and pro-inflammatory (IL-2(+) and IL-17(+)) cytokines in whole blood. In addition, RT-PCR analysis revealed increased mRNA expression of IL-6, IL-17, TNF-α, and NF-κB in the LPS group, while reduced by treatment with diosmin. Western blot analysis confirmed the increased protein expression of IL-1ß, TNF-α and NF-κB p65 in the LPS group and treatment of animals with diosmin reversed these effects. The levels of cytoplasmic p-IκB-α and p-NF-κB p65 expression also were mitigated by diosmin. The histological examinations revealed protective effect of diosmin while LPS group aggravated lung injury. These results support the potential for diosmin to be investigated as a potential agent for the treatment of lung injury and inflammatory diseases.


Asunto(s)
Lesión Pulmonar Aguda/metabolismo , Diosmina/metabolismo , Regulación hacia Abajo/fisiología , Regulación de la Expresión Génica/fisiología , Inflamación/metabolismo , FN-kappa B/metabolismo , Receptores de Antígenos de Linfocitos T/metabolismo , Lesión Pulmonar Aguda/inducido químicamente , Animales , Interleucina-17/metabolismo , Interleucina-1beta/metabolismo , Interleucina-2/metabolismo , Interleucina-6/metabolismo , Lipopolisacáridos/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Transducción de Señal/fisiología , Factor de Transcripción ReIA/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
11.
Pharmacol Res ; 99: 248-57, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26149470

RESUMEN

Psoriasis is one of the most common skin disorders characterized by erythematous plaques that result from hyperproliferative keratinocytes and infiltration of inflammatory leukocytes into dermis and epidermis. Recent studies suggest that IL-23/IL-17A/IL-22 cytokine axis plays an important role in the pathogenesis of psoriasis. The small molecule bromodomain and extraterminal domain (BET) inhibitors, that disrupt interaction of BET proteins with acetylated histones have recently demonstrated efficacy in various models of inflammation through suppression of several pathways, one of them being synthesis of IL-17A/IL-22 which primarily depends on transcription factor, retinoic acid receptor-related orphan receptor C (RORC). However, the efficacy and mechanistic aspect of a BET inhibitor in mouse model of skin inflammation has not been explored previously. Therefore, this study investigated the role of BET inhibitor, JQ-1 in mouse model of psoriasis-like inflammation. Mice were topically applied imiquimod (IMQ) to develop psoriasis-like inflammation on the shaved back and ear followed by assessment of skin inflammation (myeloperoxidase activity, ear thickness, and histopathology), RORC and its signature cytokines (IL-17A/IL-22). JQ-1 suppressed IMQ-induced skin inflammation as reflected by a decrease in ear thickness/myeloperoxidase activity, and RORC/IL-17A/IL-22 expression. Additionally, a RORα/γ agonist SR1078 was utilized to investigate the role of RORC in BET-mediated skin inflammation. SR1078 reversed the protective effect of JQ-1 on skin inflammation at both histological and molecular levels in the IMQ model. The current study suggests that BET bromodomains are involved in psoriasis-like inflammation through induction of RORC/IL-17A pathway. Therefore, inhibition of BET bromodomains may provide a new therapy against skin inflammation.


Asunto(s)
Aminoquinolinas/farmacología , Inflamación/inducido químicamente , Interleucina-17/metabolismo , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo , Psoriasis/inducido químicamente , Transducción de Señal/efectos de los fármacos , Piel/efectos de los fármacos , Animales , Azepinas/farmacología , Modelos Animales de Enfermedad , Imiquimod , Inflamación/metabolismo , Interleucinas/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Psoriasis/metabolismo , Triazoles/farmacología , Interleucina-22
12.
Phys Chem Chem Phys ; 17(33): 21716-28, 2015 Sep 07.
Artículo en Inglés | MEDLINE | ID: mdl-26234250

RESUMEN

Bi2O3-SnO2 nanocomposites formed at a nominal molar ratio of 3 : 1 and loaded with Pd/Pt nanoparticles synthesized by a sol gel-hydrothermal method with the aid of a template were thoroughly characterized by X-ray diffraction, TEM-EDX, N2 sorptiometry, diffuse reflectance UV-Vis, FTIR, photoluminescence and electrical conductivity. It has been shown that Pd and Pt stimulate the existence of ß-Bi2O3 and SnO2, respectively together with the key component Bi2Sn2O7. The photocatalytic results indicate that Pd/ß-Bi2O3-Bi2Sn2O7 revealed a remarkable performance for the degradation of methylene blue (MB) dye as compared to the Pt/SnO2-Bi2Sn2O7 and Bi2O3-SnO2 samples in both the UV and visible regions. The enhanced photocatalytic activity of the Pd/ß-Bi2O3-Bi2Sn2O7 nanocomposite is primarily attributed to the broad contact between the ß-Bi2O3 and Bi2Sn2O7 phases, which indicates high mesoporosity and heterojunction structures resulting in separation efficacy between photo-induced electron-hole pairs. Specifically, the photosensitive ß-Bi2O3 is easily excited and released electrons to be accepted by Bi2Sn2O7 and Pd that might be deposited in the interlayer between ß-Bi2O3 and Bi2Sn2O7. The degradation mechanism of MB over Pd/ß-Bi2O3-Bi2Sn2O7 in the visible region showed that the dye degradation proceeds through evolution of ˙O2(-) and ˙OH radicals as evaluated using photoluminescence and free radical trapping experiments. An insight into the electrical properties including the dielectric constant and impedance of the materials indicates that Pd/ß-Bi2O3-Bi2Sn2O7 has the highest conductivity based on increasing the ionic transport and defects at the ß-Bi2O3/Bi2Sn2O7 heterojunction. This material displayed an improved photocurrent response of a higher power conversion efficiency, exceeding that of Pt/SnO2-Bi2Sn2O7 and SnBi3 by 50% and 250%, respectively, in dye-sensitized solar cells. Picosecond-resolved photoluminescence (PL) and polarization gated PL anisotropy measurements were combined to clarify the process of FRET from the excited Pd/ß-Bi2O3-Bi2Sn2O7 to SD N719. This indicates that the latter structure can be proposed as a multifunctional candidate for use in dye-sensitized solar cells, as an electrical material and as an efficient photocatalyst based on its versatile structure.

13.
Immunology ; 142(3): 374-83, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24460575

RESUMEN

The histamine 4 receptor (H4R) is expressed primarily on cells involved in inflammation and immune responses. Despite much research into inflammatory diseases, no drugs with favourable safety profiles are yet available for their treatment. The aim of the present study was to determine the potential anti-inflammatory effect of 4-methylhistamine (4-MeH) or JNJ77777120 (JNJ) and to explore the role of H4R in a mouse model of carrageenan (Cg) -induced pleurisy. A single dose of 4-MeH or JNJ (30 mg/kg) was administered intraperitoneally 1 hr before Cg administration. The results illustrate that both the numbers of CD4(+) , CD25(+) , CD4(+)  CD25(+) , GITR(+) , GITR(+)  IL-17A(+) -expressing T cells and the levels of T helper type 1 (Th1)/Th17 cytokines were markedly increased in both the Cg-treated and 4-MeH-treated groups, whereas the cytokines produced by Th2 cells were significantly decreased in the same groups. However, JNJ treatment significantly decreased both the number of T-cell subsets and GITR(+) , GITR(+)  IL-17A(+) -expressing T cells, and the production of Th1/Th17 cytokines. Further, JNJ up-regulated the expression of the Th2 cytokines. RT-PCR analysis revealed an increased expression of interleukin-1ß, tumour necrosis factor-α, monocyte chemoattractant protein-1 and intercellular adhesion molecule-1 in the Cg-treated and 4-MeH-treated groups, which was reduced by treatment with JNJ in lung tissues. Moreover, histological examinations revealed anti-inflammatory effects of JNJ, whereas 4-MeH worsened Cg-induced inflammation. In conclusion, the results of the present work clearly indicate that JNJ possesses important anti-inflammatory properties that are increased in 4-MeH-treated mice, suggesting that H4R are involved in pleurisy and that JNJ has an anti-inflammatory effect in associated disease conditions.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Indoles/farmacología , Metilhistaminas/farmacología , Piperazinas/farmacología , Pleuresia/tratamiento farmacológico , Pleuresia/metabolismo , Receptores Histamínicos/metabolismo , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Carragenina , Citocinas/análisis , Citocinas/inmunología , Femenino , Indoles/química , Indoles/uso terapéutico , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Inflamación/metabolismo , Metilhistaminas/química , Metilhistaminas/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Terapia Molecular Dirigida , Piperazinas/química , Piperazinas/uso terapéutico , Pleuresia/inducido químicamente , Pleuresia/inmunología , Relación Estructura-Actividad
14.
Cell Immunol ; 287(2): 112-20, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24487035

RESUMEN

Naringin, a well-known flavanone glycoside found in grapefruit and other citrus fruits, was determined to be an effective anti-inflammatory compound. We investigated the effect of naringin on the key mediators of arthritic inflammation, namely T cell subsets, CD4(+)GITR(+) expressing cells, CD4(+)CD25(+)Foxp3(+) (Treg), Th1/Th2 cytokines and inflammatory mediators. We treated Balb/c mice (p.o.) with naringin (20, 40 and 80 mg/kg) for 14 days. Compared with the vehicle-treated and arthritic-control mice, the naringin treatment demonstrated a considerable decrease in the level of T cells, CD4(+)GITR(+), Th1 cytokine and inflammatory mediator expressions. In contrast, naringin treatment resulted in significantly up-regulated Treg and Th2 cytokine levels. Therefore, the naringin-induced inhibition of the T cells, various pro-inflammatory cytokines and inflammatory mediators that facilitate cellular infiltration into the joints might have contributed to its anti-arthritic activity. Our data suggest that naringin diminished the AIA in mice and it could be a potential alternative/adjunct treatment for RA.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Artritis/terapia , Enfermedades Autoinmunes/terapia , Citrus paradisi/química , Flavanonas/uso terapéutico , Subgrupos de Linfocitos T/efectos de los fármacos , Linfocitos T Reguladores/efectos de los fármacos , Animales , Artritis/inmunología , Enfermedades Autoinmunes/inmunología , Antígenos CD4/metabolismo , Células Cultivadas , Citocinas/metabolismo , Progresión de la Enfermedad , Femenino , Factores de Transcripción Forkhead/metabolismo , Proteína Relacionada con TNFR Inducida por Glucocorticoide/metabolismo , Mediadores de Inflamación/metabolismo , Subunidad alfa del Receptor de Interleucina-2/metabolismo , Ratones , Ratones Endogámicos BALB C , Subgrupos de Linfocitos T/inmunología , Linfocitos T Reguladores/inmunología , Balance Th1 - Th2
15.
Cytokine ; 68(2): 76-85, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24845796

RESUMEN

Rheumatoid arthritis (RA) is one of the major autoimmune diseases of global prevalence. Irrespective of much research in RA disease, no drugs with capable safety profiles are yet available. Poly(ADP-ribose) polymerase-1 (PARP-1) synthesizes and transfers ADP ribose polymers to target proteins, and regulates DNA repair and genomic integrity maintenance. PARP-1 also plays a crucial role in the progression of the inflammatory response, and its inhibition confers protection in several models of inflammatory disorders. We investigated the possible anti-arthritic effects of the PARP-1 inhibitor 5-aminoisoquinolinone (5-AIQ) in a mouse model of adjuvant induced arthritis (AIA). In this study, we examined the effects of 5-AIQ on the key mediators of arthritic inflammation, namely, edema and arthritic score, T cell subsets, regulatory T (Treg) cells, IL-17A, GITR expressing cells, NF-kB p65, IkB-α and pro and anti-inflammatory mediators mRNA expression levels. PARP-1 inhibition 5-AIQ treatment significantly attenuated the severity of AIA, reduced the arthritis scores, a substantial reduction in the levels of T cell subsets, IL-17A, NF-kB p65, GITR expressing cells, and as well as the pro-inflammatory mediators. However, 5-AIQ significantly up-regulated the number of Tregs cells, IkB-α levels and mRNA expression of anti-inflammatory mediators. Our results suggest that treatment with 5-AIQ attenuated AIA in mice might offer a promising alternative/adjunct treatment for RA.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Artritis Experimental/prevención & control , Inhibidores Enzimáticos/farmacología , Interleucina-17/metabolismo , Isoquinolinas/farmacología , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Linfocitos T Reguladores/inmunología , Animales , Artritis Experimental/enzimología , Antígenos CD4/metabolismo , Modelos Animales de Enfermedad , Edema/inmunología , Edema/patología , Inhibidores Enzimáticos/uso terapéutico , Femenino , Citometría de Flujo , Factores de Transcripción Forkhead/metabolismo , Factor de Transcripción GATA3/genética , Factor de Transcripción GATA3/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Proteína Relacionada con TNFR Inducida por Glucocorticoide/metabolismo , Proteínas I-kappa B/metabolismo , Mediadores de Inflamación/metabolismo , Subunidad alfa del Receptor de Interleucina-2/metabolismo , Recuento de Linfocitos , Ratones Endogámicos BALB C , Inhibidor NF-kappaB alfa , Poli(ADP-Ribosa) Polimerasas/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Linfocitos T Reguladores/efectos de los fármacos , Factor de Transcripción ReIA/metabolismo
16.
Immunol Invest ; 43(3): 197-211, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24393059

RESUMEN

Despite extensive research into inflammatory diseases to date, no drugs with favourable safety profiles are available for treatment. Euphorbia hirta (E. hirta) is a tree that is locally used as a traditional medicine in Africa and Australia to treat numerous diseases such as hypertension, antipyretic and anti-inflammatory activities. The aim of the present study was to determine the potential anti-arthritic effects of E. hirta in mouse models of adjuvant induced arthritis (AIA). We treated BALB/c mice with (p.o.) E. hirta (25, 50, 100, and 200 mg/kg) daily (13 days) beginning at the onset of AIA. We examined the effect of E. hirta on key mediators of arthritic-inflammation, including pro-inflammatory (IL-2, IFN-γ, and TNF-α) and anti-inflammatory (IL-4 and IL-5) cytokines, T-cell activation markers (CD25/CD69), and co-stimulatory molecules (CD80/CD86). We also examined the inflammatory mediators (PGE2 and LTB4) response. E. hirta-treated mice showed a substantial reduction in the levels of pro-inflammatory cytokines, down regulated cell activation markers and co-stimulatory molecules, and up regulated anti-inflammatory cytokines. E. hirta decreased the levels of inflammatory-mediators in AIA animals. Supplementation with an E. hirta extract may be a promising treatment for arthritic and inflammatory diseases.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Euphorbia , Mycobacterium tuberculosis/inmunología , Fitoterapia/métodos , Linfocitos T/inmunología , Animales , Antiinflamatorios/administración & dosificación , Antígenos Bacterianos/inmunología , Antígenos CD/metabolismo , Artritis Experimental/inmunología , Células Cultivadas , Citocinas/metabolismo , Modelos Animales de Enfermedad , Femenino , Humanos , Mediadores de Inflamación/metabolismo , Activación de Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Aceites/administración & dosificación , Parafina/administración & dosificación , Extractos Vegetales/administración & dosificación
17.
Heliyon ; 10(10): e31351, 2024 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-38831816

RESUMEN

Water pollution represents one of the most important problems affecting the health of living organisms, so it was necessary to work on the formation of active materials to get rid of pollutants. In this study, Titanium dioxide (TiO2) doping Zinc oxide (ZnO) nanocomposites were produced via simple sonication method at 500 Hz in ethanol medium. At different weight concentrations (2.5, 5, 7.5, and 10 %). The morphology, structure configuration, chemical bonding, crystalline phase, and surface properties of obtained nanocomposites were characterized via FESEM, BET, XRD, XPS, RAMAN and FTIR instrumentation. The nanocomposites were employed as an adsorbent to eliminate the methyl orange (MO) and Indigo Carmine (IC) dyes from an aqueous solution. Batch removal experiments revealed that the elimination of MO and IC dyes by the TiZnO surface was pH and doping Ti concentration-dependent, with maximum removal occurring at pH = 7 for MO and pH = 3 for IC contaminants at 10 % doping Ti concentration (Ti (10 %)@ZnO). Langmuir model fit the absorptive removal of MO and IC dyes into the Ti (10 %)@ZnO surface well. The maximal removal capacity of Ti (10 %)@ZnO nanocomposite was found to be 994.24 mg. g-1 for MO and 305.39 mg. g-1 for IC. The Ti (10 %)@ZnO nanocomposite showed remarkable high stability towards the removal of both dyes through consecutive four cycles.

18.
Sci Rep ; 14(1): 9636, 2024 04 26.
Artículo en Inglés | MEDLINE | ID: mdl-38671055

RESUMEN

In consideration of the chromones' therapeutic potential and anticancer activity, a new series of chromanone derivatives have been synthesized through a straightforward reaction between 6-formyl-7-hydroxy-5-methoxy-2-methylchromone (2) and various organic active compounds. The cytotoxic activity of the newly synthesized congeners was investigated against MCF-7 (human breast cancer), HCT-116 (colon cancer), HepG2 (liver cancer), and normal skin fibroblast cells (BJ1). The obtained data indicated that compounds 14b, 17, and 19 induce cytotoxic activity in the breast MCF7, while compounds 6a, 6b, 11 and 14c showed highly potent activity in the colon cancer cell lines. Overall, the results demonstrate that the potential cytotoxic effects of the studied compounds may be based on their ability to induce DNA fragmentation in cancer cell lines, down-regulate the expression level of CDK4 as well as the anti-apoptotic gene Bcl-2 and up-regulate the expression of the pro-apoptotic genes P53 and Bax. Furthermore, compounds 14b and 14c showed a dual mechanism of action by inducing apoptosis and cell cycle arrest. The docking studies showed that the binding affinity of the most active cytotoxic compounds within the active pocket of the CDK4 enzyme is stronger due to hydrophobic and H-bonding interactions. These results were found to be consistent with the experimental results.


Asunto(s)
Antineoplásicos , Apoptosis , Cromonas , Simulación del Acoplamiento Molecular , Humanos , Cromonas/química , Cromonas/farmacología , Cromonas/síntesis química , Antineoplásicos/farmacología , Antineoplásicos/química , Antineoplásicos/síntesis química , Apoptosis/efectos de los fármacos , Células MCF-7 , Línea Celular Tumoral , Células HCT116 , Células Hep G2 , Quinasa 4 Dependiente de la Ciclina/metabolismo , Puntos de Control del Ciclo Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Relación Estructura-Actividad , Proteína p53 Supresora de Tumor/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/genética , Ensayos de Selección de Medicamentos Antitumorales
19.
Inflammopharmacology ; 21(2): 161-8, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22710830

RESUMEN

Euphorbia hirta L. (Euphorbiaceae) (E. hirta) is a tree locally used as a traditional medicine in Africa and Australia to treat numerous diseases such as hypertension, respiratory ailments, tumors, wounds, antipyretic, anti-inflammatory activities, etc. Therefore, we undertook to investigate their immunomodulatory effect on T lymphocytes (CD3+, CD4+ and CD8+ receptors) and Th1 cytokines (IL-2, TNF-α, IFN-γ) in a dose-dependent manner. E. hirta ethanol extract at 25, 50, 100 and 200 mg/kg doses was given orally for 7 days from the day of immunization. E. hirta maximum inhibition at 100 and 200 mg/kg p.o. was found to significantly block the production of the cell-mediated immune response, (CD3+, CD4+ and CD8+ receptors) and (IL-2, TNF-α, IFN-γ) and also prolongs graft rejection. E. hirta also showed a decrease of delayed hypersensitivity (DTH) response and dose-related decrease in the primary antibody response, respectively. Based on the data, it can be suggested that E. hirta is a potent and non-toxic immunosuppressor, which can be further explored for the development of potent immunosuppressor.


Asunto(s)
Euphorbia/química , Inmunosupresores/farmacología , Extractos Vegetales/farmacología , Animales , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Femenino , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/inmunología , Hipersensibilidad/tratamiento farmacológico , Hipersensibilidad/inmunología , Tolerancia Inmunológica/efectos de los fármacos , Tolerancia Inmunológica/inmunología , Inmunidad Celular/efectos de los fármacos , Inmunidad Celular/inmunología , Inmunidad Humoral/efectos de los fármacos , Inmunidad Humoral/inmunología , Interferón gamma/inmunología , Interleucina-2/inmunología , Ratones , Ratones Endogámicos BALB C , Factor de Necrosis Tumoral alfa/inmunología
20.
J Mech Behav Biomed Mater ; 146: 106075, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37591054

RESUMEN

Calcium silicate cements have been greatly developed in the last decades through different approaches. Among these approaches, the inclusion of antibacterial agents or addition of metal oxides. Herein, calcium silicate cement containing fluorine (CFS) was developed from sodium fluorosilicate precursor for the first time using chemical perception method. Afterwards, metal oxide Bi2O3 or MgO or ZrO2 was individually mixed with CFS powder and blended together using Polycaprolactone polymer (PCL). The cement mixtures were characterized using DSC, XRD, FTIR and SEM/EDX to determine the effect of metal oxide on the pure CFS. Furthermore, mechanical, antibacterial and cell viability properties were evaluated for the developed CFS mixture cements. Moreover, these CFS mixture cements were implanted in male Wistar rats to determine the effect of metal oxides on the rate of bone reformation. The findings of physicochemical and morphological characterization showed no remarkable effects on the pure CFS after mixing with each metal oxide. However, enhanced compressive strengths (up to 104.07N/cm2), antibacterial activity and cell viability (up to 96%) were achieved for the CFS cement mixtures. Finally, the in vivo studies confirmed the biocompatibility of the CFS cement mixtures and especially those mixed with Bi2O3 or ZrO2. Therefore, this study supports that CFS blends with Bi2O3 or ZrO2 can be novel promising cementing materials for bone restoration.


Asunto(s)
Cementos para Huesos , Calcio , Masculino , Ratas , Animales , Ratas Wistar , Cementos para Huesos/farmacología , Antibacterianos/farmacología , Cementos de Ionómero Vítreo , Óxidos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA